Carfilzomib: A cause of drug associated thrombotic microangiopathy

Abstract Carfilzomib is a selective proteosome inhibitor approved for treatment of relapsed and refractory multiple myeloma. Recent reports have linked exposure to carfilzomib with development of thrombotic microangiopathy (TMA). We describe two cases of biopsy proven thrombotic microangiopathy that...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Transfusion and apheresis science 2016-06, Vol.54 (3), p.401-404
Hauptverfasser:	Qaqish, Ibrahim, Schlam, Ilana M, Chakkera, Harini A, Fonseca, Rafael, Adamski, Jill
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Apheresis Female Health technology assessment Hematology, Oncology and Palliative Medicine Humans Male Multiple Myeloma - drug therapy Oligopeptides - administration & dosage Oligopeptides - adverse effects Plasma Exchange Therapeutic plasma exchange Thrombotic Microangiopathies - chemically induced Thrombotic Microangiopathies - therapy Thrombotic microangiopathy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!